Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

The Bill & Melinda Gates Foundation has approved a three-year grant that will lead to an expansion of the pharmacometric research group within MORU’s Department of Clinical Pharmacology.

Head of Pharmacology Joel Tarning will be principal investigator for the grant, Model-based drug development platforms for antimalarials, which will be based at MORU in Bangkok, Thailand.

Malaria is still the most important parasitic disease of humans, killing almost 2,000 people each day, mainly young children under the age of five in tropical areas. The increasing prevalence of artemisinin-resistant falciparum malaria in Southeast Asia is now threatening our ability to control and eliminate malaria in the region and elsewhere and jeopardizing aspirations to eliminate malaria. ACT partner drug resistance is following so there is an urgent need now for novel, safe and effective antimalarial combination treatments with different mechanism of actions. However, drug development is slow and costly and in need of optimization to accelerate the delivery of novel antimalarial drugs and combinations in the market.

The overall goal of the proposed research, which will be done at MORU Pharmacology, is to develop a novel model-based platform for antimalarial drug development and optimize the use of existing antimalarial drugs. This could accelerate the development of new antimalarial drugs substantially, reduce costs and de-risk the process of bringing new antimalarial drug combinations to clinical care.

For more information, kindly contact John Bleho, john@tropmedres.ac.

Similar stories

Check-list recommended to improve reporting of microscopy methods and results in malaria studies

MORU Bangkok Publication Research

A study to explore the variations of how microscopy methods are reported in published malaria studies has recommended standardised procedures should be implemented for methodological consistency and comparability of clinical trial outcomes.

Susie Dunachie awarded flagship NIHR career development award

Awards & Appointments MORU Bangkok

Susie Dunachie joins a prestigious group of leading health researchers in the latest cohort of NIHR Global Research Professors. These awards fund research leaders of the future to promote effective translation of research and to strengthen health, public health and care research leadership at the highest academic levels. Research conducted by Global Research Professors directly benefits people in LMICs. A Consultant in Infectious Diseases and Medical Microbiology, Susie works on the development of a vaccine to prevent death from melioidosis in people with type 2 diabetes mellitus in LMICs, and supports vaccine research in Thailand. Congratulations!

The COVID-19 vaccine: do we know enough to end the pandemic?

MORU Bangkok Research

Blog by Rima Shretta. Preliminary efficacy results from three vaccine candidates currently in Phase 3 trials have shown an efficacy of more than 90% against the development of symptomatic COVID-19. While these results are promising, all vaccines are in relatively early stages of testing. A comprehensive and transparent roadmap is urgently needed, to determine how limited doses of the first vaccines to be licensed will be distributed, together with which groups will initially be prioritized.

New study on the risk of Plasmodium vivax parasitaemia after Plasmodium falciparum malaria

MORU Bangkok Publication Research

A new study quantifying the high risk of Plasmodium vivax parasitaemia after treatment of Plasmodium falciparum malaria aims to identify populations in which a policy of universal radical cure, combining artemisinin-based combination therapy with a hypnozoitocidal antimalarial drug, would be most beneficial.

Applicability of COVID-19 vaccine trial results to low-and-middle-income countries

COVID-19 MORU Bangkok

In the next few months, the first Phase 3 COVID-19 vaccine trials – the majority of them in upper-middle or high-income countries and in specific target populations like young adults – will report their results. How relevant will their study results be for low-resource settings?

Congratulations new NDM professors

Awards & Appointments LOMWRU MORU Bangkok

The University of Oxford has awarded CTMGH two new Professors. Elisabeth Ashley - UK-trained physician who specialises in infectious diseases and medical microbiology & virology, and Director of the Lao-Oxford-Mahosot Hospital-Wellcome Trust Research Unit (LOMWRU) in Lao PDR since 2019, Liz is conferred the title of Professor of Tropical Medicine. Stuart Blacksell - Senior Research Scientist based at the Mahidol-Oxford Tropical Medicine Research Unit (MORU) in Thailand, Stuart is conferred the title of Professor of Tropical Microbiology.